In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

NEW YORK (AP) — Stocks are rising on Wall Street Thursday, even as President Donald Trump’s latest tariffs kicked into effect ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Eli Lilly’s oral obesity drug orforglipron helped patients lose roughly 11% of their body weight, about 25 pounds, in a ...

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...